tradingkey.logo
tradingkey.logo
Search

Insmed Inc

INSM
Add to Watchlist
103.380USD
0.0000.00%
Close 06/26, 16:00ETQuotes delayed by 15 min
22.15BMarket Cap
LossP/E TTM

TradingKey Stock Score of Insmed Inc

Currency: USD Updated: 2026-06-26

Key Insights

Insmed Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 5 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 197.87.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Insmed Inc's Score

Industry at a Glance

Industry Ranking
5 / 387
Overall Ranking
41 / 4566
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Insmed Inc Highlights

StrengthsRisks
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 98.69% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 606.42M.
Undervalued
The company’s latest PE is -17.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 226.45M shares, decreasing 3.77% quarter-over-quarter.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 1.77M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.74.

Analyst Rating

Based on 23 analysts
Buy
Current Rating
197.868
Target Price
+89.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Insmed Inc?

The TradingKey Stock Score provides a comprehensive assessment of Insmed Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Insmed Inc’s performance and outlook.

How do we generate the financial health score of Insmed Inc?

To generate the financial health score of Insmed Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Insmed Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Insmed Inc.

How do we generate the company valuation score of Insmed Inc?

To generate the company valuation score of Insmed Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Insmed Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Insmed Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Insmed Inc.

How do we generate the earnings forecast score of Insmed Inc?

To calculate the earnings forecast score of Insmed Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Insmed Inc’s future.

How do we generate the price momentum score of Insmed Inc?

When generating the price momentum score for Insmed Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Insmed Inc’s prices. A higher score indicates a more stable short-term price trend for Insmed Inc.

How do we generate the institutional confidence score of Insmed Inc?

To generate the institutional confidence score of Insmed Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Insmed Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Insmed Inc.

How do we generate the risk management score of Insmed Inc?

To assess the risk management score of Insmed Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Insmed Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Insmed Inc.
KeyAI